CN113454087A - 固体形式的fgfr抑制剂化合物及其制备方法 - Google Patents

固体形式的fgfr抑制剂化合物及其制备方法 Download PDF

Info

Publication number
CN113454087A
CN113454087A CN202080014076.3A CN202080014076A CN113454087A CN 113454087 A CN113454087 A CN 113454087A CN 202080014076 A CN202080014076 A CN 202080014076A CN 113454087 A CN113454087 A CN 113454087A
Authority
CN
China
Prior art keywords
compound
formula
degrees
solvent
solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080014076.3A
Other languages
English (en)
Other versions
CN113454087B (zh
Inventor
付志飞
罗妙荣
孙继奎
张杨
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Original Assignee
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd filed Critical CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Publication of CN113454087A publication Critical patent/CN113454087A/zh
Application granted granted Critical
Publication of CN113454087B publication Critical patent/CN113454087B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本发明公开了式(I)化合物的固体形式、结晶形式、A晶型及其制备方法、B晶型及其制备方法，还包括所述固体形式、结晶形式、A晶型、B晶型在制备用于治疗与FGFR相关疾病的药物中的应用。
Figure DDA0003208625810000011

Description

PCT国内申请，说明书已公开。

Claims (24)

  1. PCT国内申请，权利要求书已公开。
CN202080014076.3A 2019-02-15 2020-02-14 固体形式的fgfr抑制剂化合物及其制备方法 Active CN113454087B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019101175307 2019-02-15
CN201910117530 2019-02-15
PCT/CN2020/075322 WO2020164603A1 (zh) 2019-02-15 2020-02-14 固体形式的fgfr抑制剂化合物及其制备方法

Publications (2)

Publication Number Publication Date
CN113454087A true CN113454087A (zh) 2021-09-28
CN113454087B CN113454087B (zh) 2023-01-03

Family

ID=72045201

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080014076.3A Active CN113454087B (zh) 2019-02-15 2020-02-14 固体形式的fgfr抑制剂化合物及其制备方法

Country Status (8)

Country Link
US (1) US20220177475A1 (zh)
EP (1) EP3925960B1 (zh)
JP (1) JP7355834B2 (zh)
KR (1) KR20210126634A (zh)
CN (1) CN113454087B (zh)
AU (1) AU2020220512B2 (zh)
CA (1) CA3130247C (zh)
WO (1) WO2020164603A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021089005A1 (zh) * 2019-11-08 2021-05-14 石药集团中奇制药技术（石家庄）有限公司 一种fgfr抑制剂的用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104136439A (zh) * 2012-02-23 2014-11-05 拜耳知识产权有限责任公司 取代的苯并噻吩基-吡咯并三嗪及其用途
CN104159900A (zh) * 2011-12-15 2014-11-19 拜耳知识产权有限责任公司 取代的苯并噻吩基-吡咯并三嗪及其在癌症治疗中的用途
CN104245700A (zh) * 2011-12-15 2014-12-24 拜耳制药股份公司 二取代的苯并噻吩基-吡咯并三嗪及其作为fgfr激酶抑制剂的用途
US20160136168A1 (en) * 2013-07-18 2016-05-19 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for fgfr inhibitor-resistant cancer
WO2019034076A1 (zh) * 2017-08-15 2019-02-21 南京明德新药研发股份有限公司 Fgfr抑制剂及其医药用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104159900A (zh) * 2011-12-15 2014-11-19 拜耳知识产权有限责任公司 取代的苯并噻吩基-吡咯并三嗪及其在癌症治疗中的用途
CN104245700A (zh) * 2011-12-15 2014-12-24 拜耳制药股份公司 二取代的苯并噻吩基-吡咯并三嗪及其作为fgfr激酶抑制剂的用途
CN104136439A (zh) * 2012-02-23 2014-11-05 拜耳知识产权有限责任公司 取代的苯并噻吩基-吡咯并三嗪及其用途
US20160136168A1 (en) * 2013-07-18 2016-05-19 Taiho Pharmaceutical Co., Ltd. Therapeutic agent for fgfr inhibitor-resistant cancer
WO2019034076A1 (zh) * 2017-08-15 2019-02-21 南京明德新药研发股份有限公司 Fgfr抑制剂及其医药用途

Also Published As

Publication number Publication date
AU2020220512A1 (en) 2021-09-09
CA3130247C (en) 2024-02-13
KR20210126634A (ko) 2021-10-20
CN113454087B (zh) 2023-01-03
EP3925960B1 (en) 2023-07-26
EP3925960A1 (en) 2021-12-22
JP2022520629A (ja) 2022-03-31
JP7355834B2 (ja) 2023-10-03
EP3925960A4 (en) 2022-04-27
CA3130247A1 (en) 2020-08-20
US20220177475A1 (en) 2022-06-09
WO2020164603A1 (zh) 2020-08-20
AU2020220512B2 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
US10160759B2 (en) Hydroxyethyl sulfonate of cyclin-dependent protein kinase inhibitor, crystalline form thereof and preparation method therefor
CN114174271B (zh) 吡嗪-2(1h)-酮类化合物的c晶型和e晶型及其制备方法
EP3275866B1 (en) P-toluenesulfonate for mek kinase inhibitor, and crystal form thereof and preparation method therefor
CN113454087B (zh) 固体形式的fgfr抑制剂化合物及其制备方法
CN114174270B (zh) 吡嗪-2(1h)-酮类化合物的a晶型和b晶型及其制备方法
CN114269723B (zh) 吡嗪-2(1h)-酮类化合物的d晶型及其制备方法
EP3202772B1 (en) Crystal of a complex of l-proline/sodium-glucose cotransporter 2 inhibitor
CN112939876A (zh) Mavacamten的晶型I及其制备方法
RU2810067C2 (ru) Соединение ингибитора FGFR в твердой форме и способ его получения
CN111848580B (zh) 含1,2,4-三嗪-3,5-二酮的喹啉类化合物的晶型及其制备方法和应用
CN111606891B (zh) (1,1,1-三氯-2)氨基甲酸酯类衍生物及其制备方法和应用
CN110903291B (zh) 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的盐、盐的晶型及制备方法
EP3819297A1 (en) Crystal forms of thiazole compound and application thereof
KR20240004588A (ko) 피롤로피리미딘류 화합물의 결정형 및 이의 제조 방법
CN116685588A (zh) 吡啶并吡咯类化合物的晶型、制备方法及其应用
CN117677615A (zh) 一种螺环化合物的盐型、晶型及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant